Copyright
©The Author(s) 2022.
World J Clin Oncol. Jun 24, 2022; 13(6): 448-472
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448
Table 2 Ongoing clinical trials investigating combinations of immune checkpoint inhibitors and anti-vascular endothelial growth factors factors
NCT | Phase | Study drugs | Treatment line | Endpoint | Estimated End of Trial | |
NCT03794440 | 2/3 | SINTILIMAB + BEVACIZUMABBIOSIMILAR | 1 | OS, ORR | December 2022 | |
NCT03970616 | 1b/2 | DURVALUMAB + TIVOZANIB | 1 | Safety | August 2022 | |
NCT03973112 | 2 | HLX-10+BEVACIZUMAB BIOSIMILAR | 1 | ORR | June 2022 |
- Citation: Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472
- URL: https://www.wjgnet.com/2218-4333/full/v13/i6/448.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i6.448